GlassScriptPhysician profile
Deep Mahapatra
NPI 1053874115
$1,478.00
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $766 · 2024: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $458.05 | 2023-2024 | Farxiga, Breztri |
| Abbvie INC. | $247.20 | 2023-2024 | |
| Lilly USA, LLC | $215.25 | 2023-2024 | Mounjaro, Zepbound |
| Silk Road Medical, INC. | $178.18 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Pfizer INC. | $152.02 | 2023-2024 | |
| Exact Sciences Corporation | $88.38 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $33.91 | 2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $25.73 | 2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $21.66 | 2024 | Rybelsus, Ozempic |
| Dexcom, INC. | $20.78 | 2023 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $19.14 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $17.70 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Mahapatra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.